Farmers & Merchants Investments Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 1.7% during the second quarter, Holdings Channel reports. The firm owned 46,359 shares of the company’s stock after buying an additional 760 shares during the period. Farmers & Merchants Investments Inc.’s holdings in Eli Lilly and were worth $3,815,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LLY. Private Capital Advisors Inc. boosted its stake in shares of Eli Lilly and by 9.7% in the first quarter. Private Capital Advisors Inc. now owns 384,564 shares of the company’s stock worth $32,346,000 after buying an additional 34,141 shares during the period. Bank of Montreal Can boosted its stake in shares of Eli Lilly and by 3.5% in the first quarter. Bank of Montreal Can now owns 904,360 shares of the company’s stock worth $76,066,000 after buying an additional 30,775 shares during the period. Gradient Investments LLC boosted its stake in shares of Eli Lilly and by 8.3% in the first quarter. Gradient Investments LLC now owns 85,342 shares of the company’s stock worth $7,178,000 after buying an additional 6,523 shares during the period. CrestPoint Capital Management LLC boosted its stake in shares of Eli Lilly and by 320.7% in the first quarter. CrestPoint Capital Management LLC now owns 12,200 shares of the company’s stock worth $1,026,000 after buying an additional 9,300 shares during the period. Finally, Beutel Goodman & Co Ltd. bought a new stake in shares of Eli Lilly and during the first quarter worth $161,084,000. Hedge funds and other institutional investors own 75.61% of the company’s stock.

Eli Lilly and Company (NYSE:LLY) traded down 0.47% during mid-day trading on Friday, reaching $81.15. The company had a trading volume of 2,446,392 shares. The firm’s 50 day moving average price is $82.91 and its 200-day moving average price is $81.72. The company has a market capitalization of $85.61 billion, a price-to-earnings ratio of 35.11 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the company posted $0.86 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio is presently 90.04%.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/farmers-merchants-investments-inc-has-3-82-million-stake-in-eli-lilly-and-company-nyselly/1479539.html.

LLY has been the subject of a number of analyst reports. BMO Capital Markets cut Eli Lilly and from a “market perform” rating to an “underperform” rating and decreased their price objective for the stock from $73.00 to $71.00 in a research note on Monday, April 17th. Morgan Stanley cut Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price target for the company. in a research note on Monday, April 17th. Cowen and Company increased their price target on Eli Lilly and from $85.00 to $95.00 and gave the company an “outperform” rating in a research note on Monday, April 17th. Piper Jaffray Companies reiterated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research note on Monday, April 17th. Finally, Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Tuesday, April 18th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $88.27.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the transaction, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 669,733 shares of company stock worth $55,845,287. Corporate insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.